ATE468851T1 - Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen - Google Patents
Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungenInfo
- Publication number
- ATE468851T1 ATE468851T1 AT03771947T AT03771947T ATE468851T1 AT E468851 T1 ATE468851 T1 AT E468851T1 AT 03771947 T AT03771947 T AT 03771947T AT 03771947 T AT03771947 T AT 03771947T AT E468851 T1 ATE468851 T1 AT E468851T1
- Authority
- AT
- Austria
- Prior art keywords
- dyslipidemia
- treatment
- lipid disorders
- ppar alpha
- selective compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39951802P | 2002-07-30 | 2002-07-30 | |
PCT/US2003/023499 WO2004010992A1 (en) | 2002-07-30 | 2003-07-25 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE468851T1 true ATE468851T1 (de) | 2010-06-15 |
Family
ID=31188591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03771947T ATE468851T1 (de) | 2002-07-30 | 2003-07-25 | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen |
Country Status (8)
Country | Link |
---|---|
US (1) | US7297715B2 (de) |
EP (1) | EP1539137B1 (de) |
JP (1) | JP4505327B2 (de) |
AT (1) | ATE468851T1 (de) |
AU (1) | AU2003256911B2 (de) |
CA (1) | CA2493913A1 (de) |
DE (1) | DE60332738D1 (de) |
WO (1) | WO2004010992A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101078098B1 (ko) | 2003-01-14 | 2011-10-28 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료 |
MXPA05010937A (es) * | 2003-04-14 | 2005-11-25 | Inst For Pharm Discovery Inc | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. |
KR20060006953A (ko) | 2003-04-30 | 2006-01-20 | 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 | 치환된 카르복실산 |
RS20060018A (en) | 2003-07-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
WO2005024057A1 (en) * | 2003-09-10 | 2005-03-17 | Galapagos Genomics N.V. | Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell |
EP1566202A1 (de) * | 2004-02-23 | 2005-08-24 | Sahltech I Göteborg AB | Verwendung von resistin-antagonisten zur behandlung von Rheumatoider arthritis |
BRPI0515015A (pt) | 2004-08-11 | 2008-07-01 | Kyorin Seiyaku Kk | derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
JPWO2006101108A1 (ja) * | 2005-03-23 | 2008-09-04 | 杏林製薬株式会社 | 新規環状アミノフェニルアルカン酸誘導体 |
WO2008091338A1 (en) * | 2007-01-23 | 2008-07-31 | Reddy Us Therapeutics, Inc. | Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
EP2612553B1 (de) | 2007-04-11 | 2016-06-08 | Omeros Corporation | Zusammensetzungen und Verfahren zur Vorbeugung und Behandlung von Suchtkrankheiten |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US8142826B2 (en) * | 2007-11-05 | 2012-03-27 | Naturex, Inc. | Extract of Fraxinus excelsior seeds and therapeutic applications therefor |
US8883721B2 (en) * | 2009-05-12 | 2014-11-11 | Mcgill University | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
US9724381B2 (en) | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
WO2011159917A2 (en) | 2010-06-16 | 2011-12-22 | The Administrators Of The Tulane Educational Fund | Growth hormone secretatogue receptor antagonists and uses thereof |
EP3323818A1 (de) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen |
CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염 |
JP2020507611A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 原発性胆汁性胆管炎の治療のための化合物および方法 |
KR101934197B1 (ko) * | 2017-06-12 | 2018-12-31 | 아주대학교산학협력단 | PPARα/γ 이중 작용 활성을 갖는 신규 화합물 및 이를 유효성분으로 함유하는 대사질환 예방 또는 치료용 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4565882A (en) * | 1984-01-06 | 1986-01-21 | G. D. Searle & Co. | Substituted dihydrobenzopyran-2-carboxylates |
US5273999A (en) * | 1991-09-10 | 1993-12-28 | Hoffmann-La Roche Inc. | Carboxylic acid leukotriene B4 antagonists |
ES2261202T3 (es) * | 1999-04-28 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Derivados de acido de triarilo como ligandos para el receptor ppar. |
FR2802808B1 (fr) * | 1999-12-22 | 2002-08-09 | Oreal | Utilisation de composes polycycliques aromatiques en tant qu'activateurs des recepteurs de type ppars dans une composition cosmetique ou pharmaceutique |
AU9287401A (en) * | 2000-09-27 | 2002-04-08 | Merck & Co Inc | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
JP2002114781A (ja) * | 2000-10-06 | 2002-04-16 | Sankyo Co Ltd | 置換縮合イミダゾール誘導体を含有する糖尿病の予防剤、治療剤 |
-
2003
- 2003-07-25 AU AU2003256911A patent/AU2003256911B2/en not_active Ceased
- 2003-07-25 CA CA002493913A patent/CA2493913A1/en not_active Abandoned
- 2003-07-25 JP JP2004524924A patent/JP4505327B2/ja not_active Expired - Fee Related
- 2003-07-25 WO PCT/US2003/023499 patent/WO2004010992A1/en active Application Filing
- 2003-07-25 EP EP03771947A patent/EP1539137B1/de not_active Expired - Lifetime
- 2003-07-25 US US10/522,646 patent/US7297715B2/en not_active Expired - Fee Related
- 2003-07-25 AT AT03771947T patent/ATE468851T1/de not_active IP Right Cessation
- 2003-07-25 DE DE60332738T patent/DE60332738D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US7297715B2 (en) | 2007-11-20 |
JP4505327B2 (ja) | 2010-07-21 |
AU2003256911B2 (en) | 2008-07-10 |
EP1539137A1 (de) | 2005-06-15 |
JP2005538109A (ja) | 2005-12-15 |
DE60332738D1 (de) | 2010-07-08 |
US20060089404A1 (en) | 2006-04-27 |
CA2493913A1 (en) | 2004-02-05 |
WO2004010992A1 (en) | 2004-02-05 |
EP1539137B1 (de) | 2010-05-26 |
AU2003256911A1 (en) | 2004-02-16 |
EP1539137A4 (de) | 2007-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60332738D1 (de) | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen | |
ATE400564T1 (de) | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen | |
ATE319453T1 (de) | Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
ATE542801T1 (de) | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine | |
DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
IL173123A0 (en) | System and method for the photodynamic treatment of burns, wounds, and related skin disorders | |
DE60223254D1 (de) | Verzögert freisetzende formulierungen von oxymorphon | |
EP1471909A4 (de) | Pharmazeutische zusammensetzung und verfahren zur behandlung von erkrankungen des zentralen nervensystems | |
DE60223694D1 (de) | Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums | |
GEP20094759B (en) | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
DK1663244T3 (da) | Pteridin-derivater til behandling af TNF-alpha-beslægtede sygdomme | |
NO20031903L (no) | Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser | |
ATE488236T1 (de) | Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen | |
DK1491212T3 (da) | Middel til behandling af søvnforstyrrelser | |
DE60132851D1 (de) | Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension | |
DK1853232T3 (da) | Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse | |
DE60022867D1 (de) | 1-Arenesulfonyl-2-Aryl-Pyrrolidin und Piperidin Derivative zur Behandlung von CNS-Erkrankungen | |
ATE359783T1 (de) | Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems | |
EE200100553A (et) | Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks | |
RU2001124802A (ru) | Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств | |
EP1551397A4 (de) | Guanidin-verbindungen als narkosemittel und zur behandlung von erkrankungen des nervensystems | |
DE50313329D1 (de) | 1-phenyl-2-dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
ATE314064T1 (de) | L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |